Clinical trial
A Randomized, Blind, Placebo-controlled, Three-way Crossover Study to Evaluate the Potential Interaction of Tunodafil Hydrochloride Tablets and Alcohol in Healthy Chinese Male Participants
NCT05976503 is registered in ClinicalTrials.gov with Yangtze River Pharmaceutical Group Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Blind, Placebo-controlled, Three-way Crossover Study to Evaluate the Potential Interaction of Tunodafil Hydrochloride Tablets and Alcohol in Healthy Chinese Male Participants
- Lead sponsor
- Yangtze River Pharmaceutical Group Co., Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 19, 2022
- Completion date
- March 21, 2023
- Enrollment
- 22 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.